New treatment approach tested for aggressive breast cancer in nigeria
NCT ID NCT03879577
Summary
This study is testing whether giving two cancer drugs—docetaxel (chemotherapy) and trastuzumab (a targeted therapy)—before surgery can help eliminate tumors in Nigerian women with HER2-positive breast cancer. The trial involves 53 women with stage II or III breast cancer who haven't had chemotherapy before. Researchers will check if the treatment completely removes cancer cells before surgery and monitor side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College Hospital, Ibadan, Nigeria
Ibadan, Nigeria
Conditions
Explore the condition pages connected to this study.